P-29 Overall survival and treatment patterns in patients with metastatic colorectal cancer (CRC): A retrospective chart review

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide and the second most diagnosed cancer in Europe. This study aimed to describe demographic and clinical characteristics, treatment patterns, and overall survival (OS) for metastatic CRC (mCRC) patients in the UK. This was an observational, single-centre, retrospective chart review of patients receiving systemic treatment (chemotherapy with or without targeted biologics), radiotherapy, surgery or best supportive care for mCRC at the University College London Hospital between 01 January 2011 to 31 December 2016. The index date was defined as the date of first confirmed diagnosis of mCRC. In total, 107 patients (mean age 58.8 years, male [52.3%] with Eastern Cooperative Oncology Group performance status 0/1 [70.4%]) met the eligibility criteria. The majority of patients were white (73.8%), had grade 2 or moderately differentiated tumours (59.8%) and had not undergone prior resection (86.0%). The most commonly received first- and second-line therapies included FOLFOX and FOLFIRI chemotherapy regimens with or without targeted biologicals e.g., bevacizumab or cetuximab. Later lines of therapy included re-challenge with pervious chemotherapy regimens, trifluridine–tipiracil chemotherapy or a switch to palliative non-systemic therapies, e.g., surgery, radiotherapy or best supportive care. The mean time from diagnosis to initiation of first-line therapy was 53.1 days (SD: 97.1 days). The median OS for the entire cohort (from index date) was 20.2 months; one-, two- and four-year OS were 70.8%, 41.6% and 13.4%, respectively. Median OS was 17.6, 14.0, 10.5, 10.1, and 8.3 months when stratified by initiation of first-, second-, third-, fourth-, and fifth-line therapy, and the corresponding one-year OS were 64.6%, 56.0%, 42.2%, 35.5%, and 19.2%, respectively. In this real-world cohort, patients diagnosed with mCRC survive on average less than two years with limited therapeutic options, particularly following first- and second-line therapy. This highlights the need for novel treatments to improve survival in this patient population.